Core Facility for Human Stem Cell–Derived Islets
Advanced Resources for Diabetes Research
Our core facility provides cutting-edge production of human stem cell–derived islets (SC-islets) using validated, reproducible differentiation protocols (Balboa et al., Nature Biotechnology, 2022). The facility is embedded within a strong diabetes research environment at the Department of Medical Cell Biology, Uppsala University.
SERVICES OFFERED:
- Generation of SC-islets from H1 ESCs and multiple iPSC lines (including T1D donors).
- Functional assays: GSIS, perifusion, immunostaining for cell composition.
- Transplantation of SC-islets into immunodeficient mice at diverse anatomical sites.
- Creation and validation of new iPSC lines.
- SC-islets derived from CRISPR–engineered stem cells (gene editing performed by user).
PRICING:
The cost of producing SC-islets is partly covered by EXODIAB during the startup phase of the core facility, offering a valuable opportunity for islet researchers.
Additional costs apply for in vivo assays and iPSC generation.
WORKFLOW:
- Submit proposal to Joey.Lau@mcb.uu.se.
- Advisory board feasibility review.
- Planning meeting.
- Project plan with timeline and cost estimate.
- Project execution.
Uppsala University – Stem Cell Islet Core Facility